Meet the scientists of Drug Discovery & Development magazine’s GPCR Roundtable.
Suresh Poda (PhD, biochemistry), is a senior scientist at the HTS Center for Lundbeck in Paramus, N.J. The company’s research focuses on CNS disorders. While the primary targets are GPCRs—monoimmuno receptors and other GPCRs that are involved in neurotransmitter pathways—the company also studies ion channel and enzyme targets.
Charles A. Lunn (PhD, biochemistry), is a research fellow in New Lead Discovery at Schering-Plough Research Institute in Kenilworth, N.J. His group develops HTS assays. Targets include immunology and cardiovascular disease. Most of the GPCR targets investigated in recent years have utilized cell-based assays, looking at second messengers, as well as more primary readouts.
Richard Eglen (PhD, pharmacology), is president of Bio-discovery at PerkinElmer, Waltham, Mass. He has worked in drug discovery at GPCRs, as well as the development of technologies to screen compounds at GPCRs for central nervous system, cardiovascular, and metabolic disorders. His research has focused on muscarinic, serotonergic, and opioid receptors.
Filed Under: Drug Discovery